2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
Weinberg, Linda R; Albom, Mark S; Angeles, Thelma S; Breslin, Henry J; Gingrich, Diane E; Huang, Zeqi; Lisko, Joseph G; Mason, Jennifer L; Milkiewicz, Karen L; Thieu, Tho V; Underiner, Ted L; Wells, Gregory J; Wells-Knecht, Kevin J; Dorsey, Bruce D.
Bioorg Med Chem Lett
; 21(24): 7325-30, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-22041060
Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.
Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening.
Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.
Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity.
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
Three dimensional quantitative structure-activity relationship of 5H-Pyrido[4,3-b]indol-4-carboxamide JAK2 inhibitors.
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.